Traws Pharma FY2025 net income $9.2M (vs loss $166.5M); $60M PIPE with $10M upfront funds into Q1 2027

Traws Pharma, Inc.

FY2025 net income $9.2M ($0.83 basic EPS) vs net loss $166.5M ($35.21 loss/share) in FY2024; revenue $2.8M (up from $0.2M).
Cash and equivalents $3.8M at Dec 31, 2025; PIPE up to $60M with $10M upfront to fund operations into Q1 2027.
TXM (influenza) Phase 1 bridging study ongoing; expects MHRA approval for human challenge trial in Q2 2026; FDA clinical hold unresolved.
Ratutrelvir (COVID) Phase 2a topline: faster symptom resolution in PAXLOVID-ineligible patients (HR 1.31, p=0.018); fewer adverse events vs comparator.
CEO Iain Dukes and CFO Charles Parker confirmed Oct 2025; John Leaman appointed independent director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.